Antibiotics for Gram-Positive Bacterial Infections: Vancomycin, Teicoplanin, Quinupristin/Dalfopristin, Oxazolidinones, Daptomycin, Dalbavancin, and Telavancin

Infectious Disease Clinics of North America

Volumn 23, Issue 4, 2009, Pages 965-982

  Nailor, Michael D ^a,b   Sobel, Jack D ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Dalfopristin; Daptomycin; Gram positive bacteria; Linezolid; MRSA; Quinupristin; Vancomycin; VRE

Indexed keywords

AMINOGLYCOSIDE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; CEPHALOSPORIN; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; GENTAMICIN; LINEZOLID; OXAZOLIDINONE DERIVATIVE; RIFAMPICIN; STREPTOMYCIN; SULFAMETHOXAZOLE; TEICOPLANIN; TELAVANCIN; TRIMETHOPRIM; VANCOMYCIN;

ANGIONEUROTIC EDEMA; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTHRALGIA; BACTERIAL PNEUMONIA; BACTERIAL SKIN DISEASE; BLOODSTREAM INFECTION; CENTRAL NERVOUS SYSTEM INFECTION; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE INFECTION; CONSTIPATION; CONTINUOUS INFUSION; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BINDING SITE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG FEVER; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG MEGADOSE; DRUG MONITORING; DRUG PENETRATION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENDOCARDITIS; ENTEROCOCCAL INFECTION; ERYTHEMA; GASTROINTESTINAL SYMPTOM; GRAM POSITIVE INFECTION; HEMATOLOGIC DISEASE; HOSPITAL INFECTION; HOT FLUSH; HUMAN; HYPOTENSION; INJECTION SITE PAIN; LOADING DRUG DOSE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MUSCLE SPASM; MYALGIA; MYOPATHY; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; PERITONITIS; PNEUMOCOCCAL MENINGITIS; PROSTHESIS INFECTION; PROSTHETIC VALVE ENDOCARDITIS; PRURITUS; RASH; RECOMMENDED DRUG DOSE; REVIEW; SHUNT INFECTION; SIDE EFFECT; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS EPIDERMIDIS INFECTION; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS INFECTION; THROMBOCYTOPENIA; TREATMENT DURATION; VANCOMYCIN RESISTANT ENTEROCOCCUS; VANCOMYCIN RESISTANT ENTEROCOCCUS INFECTION; VANCOMYCIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; VEIN DISEASE;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; DAPTOMYCIN; GLYCOPEPTIDES; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; PEPTIDES, CYCLIC; TEICOPLANIN; VANCOMYCIN; VIRGINIAMYCIN;

EID: 70350726090     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2009.06.010     Document Type: Review

References (114)

1. Pfeiffer R.R. Structural features of vancomycin. Rev Infect Dis Nov-Dec Suppl 3 (1981) S205-S209
2. Moellering Jr. R.C. Vancomycin: a 50-year reassessment. Clin Infect Dis 42 Suppl 1 (2006) S3-S4
3. Jordan D.C., and Inniss W.E. Selective inhibition of ribonucleic acid synthesis in Staphylococcus aureus by vancomycin. Nature 184 Suppl 24 (1959) 1894-1895
4. Jordan D.C., and Mallory H.D.C. Site of action of vancomycin on Staphylococcus aureus. Antimicrob Agents Chemother 4 (1964) 489-494
5. Cunha B.A., Quintiliani R., Deglin J.M., et al. Pharmacokinetics of vancomycin in anuria. Rev Infect Dis Nov-Dec Suppl 3 (1981) S269-S272
6. Biedenbach D.J., Moet G.J., and Jones R.N. Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002). Diagn Microbiol Infect Dis 50 (2004) 59-69
7. Watanakunakorn C., and Guerriero J.C. Synergism between vancomycin and gentamicin or tobramycin for methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother 22 (1982) 903-905
8. Karchmer A.W., Archer G.C., and Dismukes W.E. Staphylococcus epidermidis causing prosthetic valve endocarditis: microbiologic and clinical observation as a guide to therapy. Ann Intern Med 98 (1983) 447-455
9. Craig W.A. Basic pharmacodynamics of antibacterials with clinical application to the use of ß-lactam, glycopeptides and linezolid. Infect Dis Clin North Am 17 (2003) 479-501
10. Hawley H.B., and Gump D.W. Vancomycin therapy of bacterial meningitis. Am J Dis Child 126 (1973) 261-264
11. Matzke G.R., Zhanel G.G., and Guay D.R.P. Clinical pharmacokinetics of vancomycin. Clin Pharm 11 (1986) 257-282
12. Redfield D.C., Underman A., Norman D., et al. Cerebrospinal fluid penetration of vancomycin in bacterial meningitis. In: Nelson J.D., and Grassi C. (Eds). Current chemotherapy and infectious disease vol. 1 (1980), American Society for Microbiology, Washington, DC 638-641
13. Graziani A.L., Lawson L.A., Gibson G.A., et al. Vancomycin concentrations in infected and non-infected human bone. Antimicrob Agents Chemother 32 (1988) 1320-1322
14. Lamer C., de Beco V., Soler P., et al. Analysis of vancomycin entry into pulmonary lung fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother 37 (1993) 281-286
15. Geraci J.E., Heilman F.R., Nichols D.R., et al. Antibiotic therapy of bacterial endocarditis: VII. Vancomycin for acute micrococcal endocarditis: preliminary report. Proc Staff Meet Mayo Clin 33 (1958) 172-181
16. Torres J.R., Sanders C.V., and Lewis A.C. Vancomycin concentration in human tissues: preliminary report. J Antimicrob Chemother 5 (1979) 475-477
17. Lake K.D., and Peterson C.D. Evaluation of a method for initiating vancomycin therapy. Experience in 205 patients. Pharmacotherapy 8 (1988) 284-286
18. Moellering Jr. R.C., Krogstad D.J., and Greenblatt D.J. Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Ann Intern Med 94 (1981) 343-346
19. American Thoracic Society and Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171 (2005) 388-416
20. Tunkel A.R., Hartman B.J., Kaplan S.L., et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 39 (2004) 1267-1284
21. Rybak M., Lomaestro B., Rotschafer J.C., et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 66 (2009) 82-98
22. Rybak M.J. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 42 (2006) S35-S39
23. Schaad V.B., McCracken G.H., and Nelson J.D. Clinical pharmacology and efficacy of vancomycin in pediatric patients. J Pediatr 96 (1980) 119-126
24. Spitzer P.G., and Eliopoulos G.M. Systemic absorption on enteral vancomycin in a patient with pseudomembranous colitis. Ann Intern Med 100 4 (1984) 533-534
25. Tedesco F., Markham R., Gurwith M., et al. Oral vancomycin for pseudomembranous colitis. Lancet 2 (1978) 226-228
26. Morse G.D., Nairn D.K., and Walshe J.J. Once weekly intraperitoneal therapy for gram-positive peritonitis. Am J Kidney Dis 4 (1987) 300-305
27. Pallotta K.E., and Manley H.J. Vancomycin use in patients requiring hemodialysis: a literature review. Semin Dial 21 (2008) 63-70
28. Huycke M.M., Sahm D.F., and Gilmore M.S. Multiple-drug resistant enterococci: the nature of the problem and an agenda for the future. Emerg Infect Dis 4 (1998) 239-249
29. Small P.M., and Chambers H.F. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug abusers. Antimicrob Agents Chemother 34 (1990) 1227-1231
30. Swayne R., Rampling A., and Newsome S.W.B. Intraventricular vancomycin for treatment of shunt-associated ventriculitis. J Antimicrob Chemother 19 (1987) 249-253
31. Gump D.W. Vancomycin for treatment of bacterial meningitis. Rev Infect Dis Nov-Dec Suppl 3 (1981) S289-S292
32. National Nosocomial Infections Surveillance System (NNIS). Nosocomial enterococci resistant to vancomycin-United States, 1989-1993. Morb Mortal Wkly Rep 42 (1993) 597-599
33. Moellering Jr. R.C. The enterococcus: a classic example of antimicrobial resistance on therapeutic options. J Antimicrob Chemother 28 (1991) 1-12
34. Noble W.C., Virani Z., and Cree R.G.A. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett 72 (1992) 195-198
35. Frieden T.R., Munsiff S.S., Low D.E., et al. Emergence of vancomycin-resistant enterococci in New York City. Lancet 342 (1993) 76-79
36. Boyce J.M. Vancomycin-resistant enterococcus. Detection, epidemiology, and control measures. Infect Dis Clin North Am 11 (1997) 367-384
37. Fridkin S.K., Edwards J.R., Courvall J.M., et al. The effect of vancomycin and third-generation cephalosporins on prevalence of vancomycin-resistant enterococci in 126 U.S. adult intensive care units. Ann Intern Med 135 (2001) 175-183
38. Centers for Disease Control and Prevention. Preventing the spread of vancomycin resistance-report from the Hospital Infection Control Practices Advisory Committee. Federal Register (1994)
39. Ena J., Dick R.W., and Jones R.N. The epidemiology of intravenous vancomycin usage in a university hospital. JAMA 269 (1993) 598-602
40. Sieradzki K., Roberts R.B., Serur D., et al. Heterogeneously vancomycin-resistant Staphylococcus epidermidis strain causing recurrent peritonitis in a dialysis patient during vancomycin therapy. J Clin Microbiol 37 (1999) 39-44
41. Jones R.N. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin Infect Dis 42 Suppl 1 (2006) S13-S24
42. Steinkraus G., White R., and Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J Antimicrob Chemother 60 (2007) 788-794
43. Howden B.P., Ward P.B., Charles P.G., et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 38 (2004) 521-528
44. Lodise T.P., Graves J., Evans A., et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 52 (2008) 3315-3320
45. Soriano A., Marco F., Martinez J.A., et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 46 2 (2008) 193-200
46. Nailor MD, Zhao JJ, Salimnia H. Daptomycin for methicillin-resistant Staphylococcus aureus bacteremia with elevated vancomycin minimum inhibitory concentrations [abstract]. IDSA/ICAAC: K3488, 2008.
47. Centers for Disease Control and Prevention. Reduced susceptibility of Staphylococcus aureus to vancomycin-Japan, 1996. Morb Mortal Wkly Rep 46 (1997) 624-626
48. Hiramatsu K., Aritaka N., Hanaki H., et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350 (1997) 1670-1673
49. Smith T.L., Pearson M.L., Wilcox K.R., et al. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 340 (1999) 493-501
50. Tenover F.C., and Moellering R.C. The rationale for revising the clinical and laboratory standards institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 44 9 (2007) 1208-1215
51. Charles P.G., Ward P.B., Johnson P.D., et al. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis 38 (2004) 448-451
52. Rybak M.J., Leonard S.N., Rossi K.L., et al. Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986-2007). J Clin Microbiol 46 (2008) 2950-2954
53. Chang S., Sievert D., Hageman J., et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 348 14 (2003) 1342-1347
54. Centers for Disease Control and Prevention Public Health Dispatch: vancomycin-resistant Staphylococcus aureus-Pennsylvania, 2002. 51(40), 2002.
55. Polk R.E., Healy D.P., Schwartz L.P., et al. Vancomycin and the red man syndrome: pharmacodynamics of histamine release. J Infect Dis 157 (1988) 502-507
56. Sorrell T.C., Collignon P.J., et al. A prospective study of adverse reactions associated with vancomycin therapy. J Antimicrob Chemother 16 2 (1985) 235-241
57. Lodise T.P., Lomaestro B., Graves J., et al. Larger vancomycin doses are associated with an increased incidence of nephrotoxicitiy. Antimicrob Agents Chemother 52 (2008) 1330-1336
58. Adrouny A., Meguerditchian S., Koo C.H., et al. Agranulocytosis related to vancomycin therapy. Am J Med 81 (1986) 1059-1061
59. Cook F.V., and Farrar W.E. Vancomycin revisited. Ann Intern Med 88 (1978) 813-818
60. Lundstrom T.S., and Sobel J.D. Antibiotics for gram-positive bacterial infections: vancomycin, teicoplanin, quinupristin/dalfopristin and linezolid. In: D. Kaye, editor. WB Saunders Co, Philadelphia. Infect Dis Clin North Am 14 2 (2000) 463-474
61. Chant C., and Rybak M.J. Quinupristin/dalfopristin (RP 59500): a new streptogramin antibiotic. Ann Pharmacother 29 (1995) 1022-1027
62. Nichterlein T., Kretschmar M., and Hof H. RP 59500, a streptogramin derivative, is effective in murine listeriosis. J Chemother 8 (1996) 107-112
63. Jones R.N., Ballow C.H., Biedenbach D.J., et al. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada. Diagn Microbiol Infect Dis 30 (1998) 437-451
64. Hussain Qadri S.M., Ueno Y., Abu Mostafa F.M., et al. In vitro activity of quinupristin/dalfopristin, RP 59500, against gram-positive clinical isolates. Chemotherapy 43 (1997) 94-99
65. Schulin T., Wennersten C.B., Ferraro M.J., et al. Susceptibilities of Legionella spp. to newer antimicrobials in vitro. Antimicrob Agents Chemother 42 (1998) 1520-1523
66. Struwig M.C., Botha P.L., and Chalkley L.J. In vitro activities of 15 antimicrobial agents against clinical isolates of South African enterococci. Antimicrob Agents Chemother 42 (1998) 2752-2755
67. Furlong W.B., and Rakowski T.A. Therapy with RP 59500 (quinupristin/dalfopristin) for prosthetic valve endocarditis due to enterococci with VanA/VanB resistance patterns. Clin Infect Dis 25 (1997) 163-164
68. Chow J.W., Davidson A., Sanford III E., et al. Superinfection with Enterococcus faecalis during quinupristin/dalfopristin therapy. Clin Infect Dis 24 (1997) 91-92
69. Hershberger E., Donabedian S., Konstantinou K., et al. Quinupristin-dalfopristin resistance in gram-positive bacteria: mechanism of resistance and epidemiology. Clin Infect Dis 38 (2004) 92-98
70. Chow J.W., Donabedian S.M., and Zervos M.J. Emergence of increased resistance to quinupristin/dalfopristin during therapy for Enterococcus faecium bacteremia. Clin Infect Dis 24 (1997) 90-91
71. Aeschlimann J.R., Zervos M.J., and Rybak M.J. Treatment of vancomycin-resistant Enterococcus faecium with RP59500 (quinupristin-dalfopristin) administered by intermittent or continuous infusion, alone, or in combination with doxycycline, in an in vitro pharmacodynamic infection model with simulated endocardial vegetation. Antimicrob Agents Chemother 42 (1998) 2710-2717
72. Muller M., and Sehimz K.L. Oxazolidinones: a novel class of antibiotics. Cell Mol Life Sci 56 (1999) 280-285
73. Tucker J.A., Allwine D.A., Grega K.C., et al. Piperazinyl oxazolidinone antibacterial agents containing a pyridine, diazine, or triazene heteroaromatic ring. J Med Chem 41 (1998) 3727-3735
74. Clemett D., and Markham A. Linezolid. Drugs 59 (2000) 815-827
75. Dresser L.D., and Rybak M.J. The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials. Pharmacotherapy 18 (1998) 456-462
76. Zurenko G.E., Yagi B.H., Schaadt R.D., et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 40 (1996) 839-845
77. Patel R., Rouse M.S., Piper K.E., et al. In vitro activity of linezolid against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, and penicillin-resistant Streptococcus pneumoniae. Diagn Microbiol Infect Dis 34 (1999) 119-122
78. Pawsey SD, Dalry-Yates PT, Wajszczuk CP, et al. U-100766 safety, toleration and pharmacokinetics after oral and intravenous administration. In: Program and abstracts of the first European Congress of Infections [abstract]. Berlin. sy13.4, 1997.
79. Lovering A.M., Zhang J., Bannister G.C., et al. Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement. J Antimicrob Chemother 50 (2002) 73-77
80. Wagenlehner F.M.E., Wydra S., Onda H., et al. Concentrations in plasma, urinary excretion, and bactericidal activity of linezolid (600 milligrams) versus those of ciprofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose. Antimicrob Agents Chemother 47 (2003) 3789-3794
81. Gemmell C.G., and Ford C.W. Virulence factor expression by gram-positive cocci exposed to subinhibitory concentrations of linezolid. J Antimicrob Chemother 50 (2002) 665-672
82. Noskin G., Siddique F., Stosor V., et al. Successful treatment of persistent vancomycin-resistant Enterococcus faecium bacteremia with linezolid and gentamicin. Clin Infect Dis 28 (1999) 689-690
83. Conte J.E., Golden J.A., Kipps J., et al. Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother 46 (2002) 1475-1480
84. Wunderink R.G., Rello J., Cammarata S.K., et al. Linezolid vs vancomycin: Analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 124 (2003) 1789-1797
85. Birmingham M.C., Rayner C.R., Meagher A.K., et al. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate use program. Clin Infect Dis 36 (2003) 159-168
86. Moise P.A., Forrest A., Birmingham M.C., et al. The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin. J Antimicrob Chemother 50 (2002) 1017-1026
87. Lipsky B.A., Itani K., Norden C., et al. Treating foot infections in diabetic patients: a randomized, multicenter; open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate. Clin Infect Dis 38 1 (2004) 17-24
88. Parodi S., Rhew D.C., and Goetz M.B. Early switch and early discharge opportunities in intravenous vancomycin treatment of suspected methicillin-resistant staphylococcal species infections. J Manag Care Pharm 9 (2003) 317-326
89. Shorr A.F., Susla G.M., and Kollef M.H. Linezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin. Crit Care Med 32 (2004) 137-143
90. Li J.Z., Willke R.J., Rittenhouse B.E., et al. Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant staphylococci: results from a randomized clinical trial. Surg Infect 4 1 (2003) 57-70
91. Brickner S.J., Hutchinson D.K., Burbachyn M.R., et al. Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections. J Med Chem 39 (1996) 673-679
92. Kaatz G.W., and Seo S.M. In vitro activities of oxazolidinone compounds U-100592 and U-100766 against staphylococcus species. Antimicrob Agents Chemother 40 (1996) 799-801
93. Rahim S., Pillai S.K., Gold H.S., et al. Linezolid-resistant, vancomycin-resistant Enterococcus faecium infection in patients without prior exposure to linezolid. Clin Infect Dis 36 (2003) E146-E148
94. Schwartz M.D., Shive D.K., and Sheikh Z.H.A. Delayed discovery of linezolid-resistant, vancomycin-resistant Enterococcus faecium: lessons learned. Clin Infect Dis 38 (2004) 155-156
95. Wilson P., Andrews J.A., and Charlesworth R. Linezolid resistance in clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 51 (2003) 186-188
96. Gerson S.L., Kaplan S.L., Bruss J.B., et al. Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother 46 (2002) 2723-2726
97. Nasraway S.A., Shorr A.F., and Kuter D.J. Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin use. Clin Infect Dis 37 (2003) 1609-1616
98. Thorne G.M., and Adler J. Daptomycin: a novel lipopeptide antibiotic. Clin Microbiol Newslett 24 (2002) 33-40
99. Tally F.P., and DeBruin M.F. Development of daptomycin for gram-positive infections. J Antimicrob Chemother 46 (2000) 523-526
100. Critchley I.A., Draghi D.C., Sahm D.F., et al. Activity of daptomycin against susceptible and multidrug-resistant gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001. J Antimicrob Chemother 51 (2003) 639-649
101. Pankuch G.A., Jacobs M.R., and Appelbaum P.C. Bactericidal activity of daptomycin against Streptococcus pneumoniae compared with eight other antimicrobials. J Antimicrob Chemother 51 (2003) 443-446
102. Golan Y., Poutsiaka D., Tozzi S., et al. Daptomycin for line-related Leuconostoc bacteremia. J Antimicrob Chemother 47 (2001) 364-365
103. Credito K., Lin G., and Appelbaum P.C. Activity of daptomycin alone and in combination with rifampin and gentamicin against Staphylococcus aureus assessed with time-kill methodology. Antimicrob Agents Chemother 51 (2007) 1504-1507
104. Bush L.M. In vitro post-antibiotic effect of daptomycin (LY-146032) against Enterococcus faecalis and methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother 33 (1989) 1198-2000
105. Fowler V.G., Boucher H.W., Corey G.R., et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 355 (2006) 653-665
106. Sakoulas G., Adler J., Thauvin-Eliopoulos C., et al. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother 50 (2006) 1581-1585
107. Jevitt L.A., Smith A.J., Williams P.P., et al. In vitro activities of daptomycin, linezolid, and quinupristin-dalfopristin against a challenge panel of staphylococci and enterococci, including vancomycin-intermediate Staphylococcus aureus and vancomycin-resistant Enterococcus faecium. Microb Drug Resist 9 (2003) 389-393
108. Patel J.B., Jevitt L.A., Hagerman J., et al. An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus. Clin Infect Dis 42 11 (2006) 1652-1653
109. Fairfax MR, Nailor MD, Painter T. et al. Vancomycin and daptomycin susceptibility testing of Staphylococcus aureus in a clinical laboratory. IDSA/ICAAC C1-140, 2008.
110. Dvorchil B.H., Brazier D., DeBruin M.F., et al. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother 47 (2003) 1318-1323
111. Bailey J., and Summers K.M. Dalbavancin: a new lipoglycopeptide antibiotic. Am J Health Syst Pharm 65 (2008) 599-610
112. Lin S., Carver P.L., and DePestel D.D. Dalbavancin: a new option for the treatment of gram-positive infections. Ann Pharmacother 40 (2006) 449-460
113. Attwood R.J., and LaPlante K.L. Telavancin: a novel lipoglycopeptide antimicrobial agent. Am J Health Syst Pharm 64 (2007) 2335-2348
114. Drew R.H. Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections. Pharmacotherapy 27 (2007) 227-249